DelveInsight supports leading pharma and biotech firms in addressing data requirements related to analyzing and forecasting low-prevalence indications. We specialize in delivering insights on precise market share uptake, price benchmarking, innovative data approaches, and identifying untapped opportunities within this niche market.
LAS VEGAS, Dec. 20, 2024 /PRNewswire/ -- At DelveInsight, we take pride in being a leading provider of pharma competitive intelligence and consulting solutions, specializing in the rare diseases domain. With over 350 epidemiology-based market reports published, our experienced team brings deep expertise and precision to navigating the complexities of the orphan disease market.
We recognize the scarcity of published data on rare patient populations, the high unmet needs, and the challenges of inaccurate diagnoses. Over the years, we have built an extensive network of Key Opinion Leaders (KOLs) working in the rare diseases domain. Their invaluable insights enable us to help our clients effectively navigate this challenging landscape.
Succeeding in the rare disease market requires more than innovation-it demands a unique business model and tailored capabilities spanning R&D, market access, and commercialization. At DelveInsight, we deliver cutting-edge strategies and operating models that empower our clients to thrive in this competitive, winner-takes-all environment.
Rare diseases impact a larger segment of the population than cancer and AIDS combined, encompassing over 7,000 unique conditions and affecting more than 300 million people worldwide. Roughly 1 in 10 individuals experience the challenges of rare diseases, and the journey to an accurate diagnosis typically takes several years, averaging around 4.8 years. Astonishingly, nearly 95% of rare diseases lack an FDA-approved treatment.
Rare disorders are accompanied by a significant financial burden, but this can be mitigated through the availability of treatments. When assessed on a per-patient per year (PPPY) basis, the economic impact of rare diseases is roughly 10 times higher than that of common diseases. The absence of treatment options for these conditions is associated with a 21.2% increase in total PPPY costs. Several leading pharmaceutical and biotechnology firms are actively engaged in various research and development initiatives aimed at creating innovative therapies to address the unique needs of patients with rare conditions. Providing these therapies to individuals facing rare conditions brings about substantial societal advantages.
Leverage DelveInsight's Custom Solutions for Rare Diseases for precise and effective results:
- DelveInsight is proud to publish more than 350 epidemiology-based market forecast reports that provide a better understanding of the rare disease market landscape.
- In-depth primary research through KOLs.
- Understand the treatment paradigms and patient journeys across different geographies including MENA and APCA
- Stay ahead in competition with the conclusions derived from the perspectives of indication-based KOL panels for different countries
- Best-in-class strategies for rare disease assets in different clinical trial phases.
- Strategizing Rare disease development business model
- Analyze the needs of the patient and caregiver in a disease state to create a patient-centric model.
- Expert opinions from key industry leaders to validate assumptions and rationale for better market assessment.
- Setting the appropriate price for a drug is highly complex due to the absence of quality-adjusted life year (QALY) health technology assessments and the scarcity of comparable benchmarks. By identifying the critical factors influencing payer purchasing decisions and leveraging the increasing emphasis on value-based pricing, we assist our partners in crafting an optimal pricing strategy that enhances their product's profitability and market share.
Ask for a proposal to find out how DelveInsight's rare disease custom solutions can assist you.
DelveInsight's Pharma Competitive Intelligence Service tailored to rare disease domain: DelveInsight's competitive intelligence services provide real-time, accurate insights across the different therapeutic domains and rare diseases is one of our fortes, providing detailed insights into advancements across rare disorders such as multiple myeloma, NF1-PN, Graves' disease, Ewing sarcoma, retinitis pigmentosa, PCPG, etc to name a few. Our services analyze competitors' pipelines, clinical trial progress, gene and cell therapy innovations, and market entry strategies, as well as regulatory updates and patent landscapes specific to rare diseases. This intelligence enables stakeholders to identify emerging threats, uncover growth opportunities, and develop targeted strategies to remain competitive in this evolving therapeutic area. Connect with us today to explore how we can help you succeed in the rare disease market.
In/Out-Licensing Opportunities: Our revolutionary service aims to provide top-tier proprietary licensing solutions, with a primary focus on delivering unparalleled consulting services. Leveraging our vast global network across the rare diseases domain, we are committed to offering the highest quality consulting services possible.
Market Assessment: DelveInsight's Market Intelligence services offer customized reports focused on specific geographical areas of interest to clients. Through thorough data analysis techniques, our analysts conduct extensive primary and secondary research, providing epidemiological and market insights, along with factors influencing the market such as drivers and barriers, industry trends, and market forecasts.
Ready to unlock the potential of your next conference? Schedule a call with our DelveInsight Business Development expert today!
DelveInsight's Healthcare Consulting Services: Healthcare Consulting Services is a comprehensive offering that provides customized solutions to clients across the healthcare industry. The consulting services are designed to help clients address their most pressing challenges and capitalize on new opportunities.
The healthcare consulting services leverage DelveInsight's extensive industry expertise, market research capabilities, and data analytics to provide clients with practical, data-driven solutions. The consultants work closely with clients to understand their unique needs and challenges and to develop tailored solutions that meet their specific requirements. DelveInsight's consulting services cover a range of areas, including market access, commercial strategy, product development, and regulatory affairs in the healthcare domain.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Why Choose DelveInsight?
The consultants at DelveInsight possess a comprehensive understanding of industry standards and are highly skilled in competitive intelligence monitoring. With a focus on continuous engagement in competitive intelligence efforts, our team utilizes advanced research and analysis tools. Leveraging our profound expertise in the pharmaceutical and biotech sciences sector, we craft insightful, concise, and thorough reports, empowering your company's leadership to make well-informed decisions.
Connect today to navigate the complexities of the life sciences industry and achieve your business objectives. Request for Proposal Now
Contact Us
Shruti Thakur
info@delveinsight.com
+14699457679
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/rare-disease-consulting-explore-how-to-address-the-low-prevalence-and-high-outstanding-therapeutics-needs-and-stay-ahead-by-understanding-the-gaps-in-the-rare-diseases-market-with-delveinsight-302335929.html
